CAS: 1346133-11-6

(S)-3-Fluoro-4-(4-((2-(3-Fluorophenyl)Pyrrolidin-1-Yl)Methyl)Phenoxy)Benzamide

LY2444296

Ly2444296, also known as FP3FBZ, is an experimental pharmaceutical compound, specifically a small-molecule antagonist designed to target a particular receptor system in the central nervous system. It is synthesized through a complex series of chemical reactions, leveraging advanced organic synthesis techniques. The primary mode of action for Ly2444296 is the selective inhibition of the norepinephrine transporter (NET), which results in increased levels of norepinephrine in the synaptic cleft. This modulation of neurotransmitter dynamics can have significant effects on mood and stress responses. The uses and applications of Ly2444296 are primarily within the realm of mental health research, with a focus on depression, anxiety, and other mood disorders. Its unique mechanism makes it a candidate for studies investigating the pathophysiological roles of norepinephrine in these conditions. Research trials are ongoing to evaluate its efficacy and safety profile, with hopes of contributing to novel therapeutic strategies for disorders where current treatments are inadequate. As an experimental compound, it remains under rigorous investigation to fully characterize its potential benefits and limitations.

LY2444296 (FP3FBZ) is an orally active and selective antagonist of kappa opioid receptor(Ki = 1 nM).